CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for ...

As predicted, the combined result of an enterprising Al Jazeera journalist hunting for a sensational angle to trip the target of his interrogation and the eccentric ramblings of an ex-President of Sri ...

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $0.96 per share a year ago.

Good afternoon, and welcome to the Spero Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in listen-only-mode. Following the company's ...

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...

The FDA's decision not to approve Spero Therapeutics' oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic ...

What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...

(JTA) — On the third night of the Republican convention, Aryeh Spero, an Orthodox rabbi with a long track record of right-wing Republican involvement, asked God to bless President Donald Trump.

The film by Akron native Pat Donovan looks at Spero's long career in Rock and Roll, starting with his days as a child working with his father, who was the producer of the syndicated music show ...

Spero Therapeutics Inc reported its financial results for the fourth quarter of 2024, revealing a diluted net loss per share of $0.38, which was slightly below the forecast of $0.36. The company’s ...